CABIO BIOTECH

CABIO Biotech established in 2004, was listed on the Shanghai Stock Exchange's STAR Market in 2019 (Stock Code: 688089). The company leverages synthetic biology as its foundational technology, with a technological platform that encompasses key modules such as strain-directed breeding, precise cellular regulation, and efficient separation and purification. Through innovative cell factory preparation methods and sustainable bio-intelligent manufacturing, CABIO provides high-quality functional ingredients, bio-based products, and innovative solutions to global customers.